This article is more than 5 years old. Information may no longer be current.
Femtosecond laser, automated microkeratome both effective in LASIK for myopia
Click Here to Manage Email Alerts
The VisuMax femtosecond laser and the Moria M2 automated microkeratome yielded similar safety and efficacy outcomes in LASIK treatment of myopia, according to a study.
VisuMax (Carl Zeiss Meditec) was associated with increased predictability.
Researchers in the interventional prospective clinical study also assessed ocular aberrations and flap thickness predictability in 60 eyes with mild to moderate myopia, 30 treated with VisuMax and 30 treated with Moria M2. Clinicians assessed keratometric, refractive and aberrometric measurements before the procedure and 3 months postop.
Manifest sphere, spherical equivalent, astigmatism, safety indices and ocular aberrations were not significantly different between the two groups at 3 months.
Other findings indicated that 86.6% of eyes in the femtosecond laser arm and 76.6% of those in the microkeratome arm fell within ±0.5 D of the intended correction. The rates for eyes that fell within ±0.25 D of the intended correction were 76.6% for femtosecond laser and 50% for microkeratome.
The mean actual flap thickness after surgery was 100.12 µm in the femtosecond laser group compared with 104.6 µm in the microkeratome group, which was a statistically significantly difference (P = .001).
“Both VisuMax and Moria M2 MK are safe and effective in treating myopia with no statistically significant difference in induction of ocular aberrations but with potential advantage for VisuMax regarding predictability,” the researchers said. “More accurate flap thickness is achieved with VisuMax femtoLASIK.” – by Rob Volansky
Disclosure s : The authors report no relevant financial disclosures.
Click Here to Manage Email Alerts